A Phase 3 interventional study of Aliskiren and Valsartan in Hypertension, sponsored by Novartis. Completed at 4 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-02-10.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies testing aliskiren in Hypertension — none open to participants now, none under way, none of them phase 3. aliskiren · Hypertension.
Among the 89 studies testing aliskiren in Hypertension, this one is the 26th largest by enrollment, is one of 11 that started in 2006, is one of 38 in phase 3, and was the 29th registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →None of the 89 studies testing aliskiren in Hypertension is open now. The open studies under Hypertension, anywhere →
aliskiren: first FDA approval 2007 (TEKTURNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 39 · Phase 4 34
First in 2001; this study’s year is marked. 11 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 601 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 253 across the 89 interventional studies. Of the 79 that completed or were terminated, 36 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
65 of 89 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
228 studies in Hypertension by Novartis: 5 open now, 6 under way, none of them phase 3. Of 219 finished, 88 (40%) have results posted.
Among the 228 studies in Hypertension by Novartis, this one is the 65th largest by enrollment of the 223 interventional ones that give a count, is one of 32 that started in 2006, is one of 108 in phase 3, and was the 92nd registered.
Novartis’s Hypertension studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 89 studies testing aliskiren in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 228 in Hypertension:
This tab as a report to print or save as PDF → With an account.
Assessment of the long-term safety and tolerability of the combination of aliskiren and valsartan (300 mg/ 320 mg) in patients with high blood pressure,followed by assessment of long-term safety and tolerability of the combination of aliskiren/valsartan/Hydrochlorothiazide(HCTZ).
Inclusion Criteria: -
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral pills of aliskiren 150 mg /valsartan 160 mg in combination for 2-weeks. The aliskiren 300 mg /valsartan 320 mg in combination for 52-weeks, optional addition of Hydrochlorothiazide (HCTZ) 12.5 mg starting from Week 10 if the blood pressure was uncontrolled (mean sitting Systolic Blood Pressure ≥ 140 and/or mean sitting Diastolic Blood Pressure ≥ 90 mmHg). The dose of Hydrochlorothiazide (HCTZ) 12.5 mg could be increased to 25 mg if blood pressure remained uncontrolled.
Drug: Aliskiren · Drug: Valsartan
For patients entering into extension, those previously treated with Hydrochlorothiazide (HCTZ) 12.5 or 25 mg in addition to aliskiren 300 mg/valsartan 320 mg were treated with aliskiren 300 mg/valsartan 320 mg/HCTZ 25 mg in the extension. Those patients who had not received HCTZ during the core study were treated with aliskiren 300 mg/valsartan 320 mg/HCTZ 12.5 mg. The HCTZ 12.5 mg dose could be increased to HCTZ 25 mg if the mean sitting Systolic Blood Pressure (msSBP) was ≥140 mmHg and/or the mean sitting Diastolic Blood Pressure (msDBP) was ≥90 mmHg for 2 consecutive visits.
Drug: Aliskiren · Drug: Valsartan · Drug: Hydrochlorothiazide (HCTZ)
Aliskiren 300 mg
Valsartan 320 mg
Hydrochlorothiazide (HCTZ) 12.5-25 mg
Overall Percentage of Patients With Adverse Events
Time frame: Month 12
Overall Percentage of Patients With Adverse Events
adverse event data obtained from both the core study and the 6 month extension study.
Time frame: Month 18
Change From Baseline in Mean Sitting Diastolic Blood Pressure.
Time frame: Baseline and Weeks 2, 4, 6, 10, 14, 18, 28, 41, and 54
Change From Baseline in Mean Sitting Systolic Blood Pressure.
Time frame: Baseline and Weeks 2, 4, 6, 10, 14, 18, 28, 41 and 54
Percentage of Patients Achieving Blood Pressure Control Target of < 140/90 mmHg
Time frame: .Weeks 2, 4, 6, 10, 14, 18, 28, 41, and 54
Change From Baseline in Mean Sitting Diastolic Blood Pressure
Time frame: Baseline and Month 18
Change From Baseline in Mean Sitting Systolic Blood Pressure
Time frame: Baseline and Month 18
Percentage of Patients Achieving Blood Pressure Control Target of < 140/90 mmHg in Extension Treatment
Time frame: Month 18
| Milestone | Core Treatment | Extension Treatment |
|---|---|---|
| Started | 601 | 0 |
| Completed | 486 | 0 |
| Not completed | 115 | 0 |
| Withdrew: Adverse event | 40 | 0 |
| Withdrew: Abnormal laboratory value(s) | 3 | 0 |
| Withdrew: Unsatisfactory therapeutic effect | 23 | 0 |
| Withdrew: Condition no longer requires study drug | 4 | 0 |
| Withdrew: Patient withdrew consent | 15 | 0 |
| Withdrew: Lost to follow-up | 23 | 0 |
| Withdrew: Administrative problems | 1 | 0 |
| Withdrew: Protocol deviation | 6 | 0 |
| Milestone | Core Treatment | Extension Treatment |
|---|---|---|
| Started | 0 | 162 |
| Completed | 0 | 145 |
| Not completed | 0 | 17 |
| Withdrew: Adverse event | 0 | 6 |
| Withdrew: Abnormal laboratory value(s) | 0 | 1 |
| Withdrew: Administrative problems | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 3 |
| Withdrew: Patient withdrew consent | 0 | 5 |
| Withdrew: Unsatisfactory therapeutic effect | 0 | 1 |
| percentage of patients | Core Treatment- Aliskiren/Valsartan & Aliskiren/Valsartan/HCTZ |
|---|---|
| Overall Percentage of Patients With Adverse Events | 76.2 |
| mmHg | Core Treatment |
|---|---|
| Week 2 (Visit 5) | -7.9 ± 7.14 |
| Week 4 (Visit 6) | -10.8 ± 7.83 |
| Week 6 (Visit 7) | -11.8 ± 8.09 |
| Week 10 (Visit 8) | -12.5 ± 8.26 |
| Week 14 (Visit 9) | -13.7 ± 7.87 |
| Week 18 (Visit 10) | -15.0 ± 8.00 |
| Week 28 (Visit 11) | -15.2 ± 7.24 |
| Week 41 (Visit 12) | -15.2 ± 7.60 |
| Week 54 (Visit 13) | -14.2 ± 7.96 |
| Endpoint (value at week 54 or LOCF) | -13.4 ± 8.75 |
| mmHg | Core Treatment |
|---|---|
| Week 2 (Visit 5) | -11.0 ± 12.42 |
| Week 4 (Visit 6) | -15.0 ± 14.03 |
| Week 6 (Visit 7) | -17.6 ± 14.10 |
| Week 10 (Visit 8) | -18.4 ± 14.37 |
| Week 14 (Visit 9) | -20.7 ± 13.42 |
| Week 18 (Visit 10) | -22.6 ± 14.01 |
| Week 28 (Visit 11) | -24.3 ± 13.70 |
| Week 41 (Visit 12) | -24.3 ± 13.27 |
| Week 54 (Visit 13) | -22.3 ± 14.51 |
| Endpoint (value at week 54 or LOCF) | -20.5 ± 16.40 |
| Percentage of patients | Core Treatment |
|---|---|
| Week 2 (Visit 5) | 32.8 |
| Week 4 (Visit 6) | 45.9 |
| Week 6 (Visit 7) | 52.4 |
| Week 10 (Visit 8) | 60.8 |
| Week 14 (Visit 9) | 68.7 |
| Week 18 (Visit 10) | 76.4 |
| Week 28 (Visit 11) | 77.9 |
| Week 41 (Visit 12) | 78.2 |
| Week 54 (Visit 13) | 71.7 |
| Endpoint (value at week 54 or LOCF) | 66.9 |
| mmHg | Extension Treatment |
|---|---|
| Change From Baseline in Mean Sitting Diastolic Blood Pressure | -18.3 ± 8.52 |
adverse event data obtained from both the core study and the 6 month extension study.
| percentage of patients | Core and Extension Treatment - Aliskiren/Valsartan/HCTZ |
|---|---|
| Overall Percentage of Patients With Adverse Events | 61.6 |
| mmHg | Extension Treatment |
|---|---|
| Change From Baseline in Mean Sitting Systolic Blood Pressure | -28.8 ± 14.80 |
| Percentage of patients | Extension Treatment |
|---|---|
| Percentage of Patients Achieving Blood Pressure Control Target of < 140/90 mmHg in Extension Treatment | 86.6 |
Collected over 18 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Core Period: Aliskiren 150 mg / Valsartan 160 mg Alone | — | 3/601 (0.5%) | 49/601 (8.2%) |
| Core Period: Aliskiren 300 mg / Valsartan 320 mg Alone | — | 14/585 (2.4%) | 185/585 (31.6%) |
| Core Period: Aliskiren / Valsartan | — | 17/601 (2.8%) | 215/601 (35.8%) |
| Core and Extension: Aliskiren / Valsartan / HCTZ 12.5 mg | — | 3/306 (1%) | 47/306 (15.4%) |
| Core and Extension: Aliskiren / Valsartan / HCTZ 25 mg | — | 6/137 (4.4%) | 26/137 (19%) |
| Core and Extension: Total | — | 26/601 (4.3%) | 251/601 (41.8%) |
| Event | Core Period: Aliskiren 150 mg / Valsartan 160 mg Alone | Core Period: Aliskiren 300 mg / Valsartan 320 mg Alone | Core Period: Aliskiren / Valsartan | Core and Extension: Aliskiren / Valsartan / HCTZ 12.5 mg | Core and Extension: Aliskiren / Valsartan / HCTZ 25 mg | Core and Extension: Total |
|---|---|---|---|---|---|---|
| PainGeneral disorders | 0/601 | 0/585 | 0/601 | 0/306 | 1/137 | 1/601 |
| Clostridium difficile colitisInfections and infestations | 0/601 | 0/585 | 0/601 | 0/306 | 1/137 | 1/601 |
| Hepatitis BInfections and infestations | 0/601 | 0/585 | 0/601 | 0/306 | 1/137 | 1/601 |
| Peritoneal abscessInfections and infestations | 0/601 | 0/585 | 0/601 | 0/306 | 1/137 | 1/601 |
| Post-traumatic painInjury, poisoning and procedural complications | 0/601 | 0/585 | 0/601 | 0/306 | 1/137 | 1/601 |
| Thermal burnInjury, poisoning and procedural complications | 0/601 | 0/585 | 0/601 | 0/306 | 1/137 | 1/601 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/601 | 0/585 | 0/601 | 0/306 | 1/137 | 1/601 |
| HypokalaemiaMetabolism and nutrition disorders | 0/601 | 0/585 | 0/601 | 0/306 | 1/137 | 1/601 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/601 | 0/585 | 0/601 | 0/306 | 1/137 | 1/601 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/601 | 1/585 | 1/601 | 0/306 | 1/137 | 2/601 |
| Event | Core Period: Aliskiren 150 mg / Valsartan 160 mg Alone | Core Period: Aliskiren 300 mg / Valsartan 320 mg Alone | Core Period: Aliskiren / Valsartan | Core and Extension: Aliskiren / Valsartan / HCTZ 12.5 mg | Core and Extension: Aliskiren / Valsartan / HCTZ 25 mg | Core and Extension: Total |
|---|---|---|---|---|---|---|
| DizzinessNervous system disorders | 15/601 | 39/585 | 49/601 | 6/306 | 7/137 | 61/601 |
| NasopharyngitisInfections and infestations | 6/601 | 39/585 | 43/601 | 10/306 | 6/137 | 54/601 |
| HeadacheNervous system disorders | 16/601 | 33/585 | 45/601 | 4/306 | 2/137 | 50/601 |
| DiarrhoeaGastrointestinal disorders | 8/601 | 27/585 | 34/601 | 9/306 | 1/137 | 42/601 |
| Upper respiratory tract infectionInfections and infestations | 2/601 | 25/585 | 28/601 | 9/306 | 2/137 | 38/601 |
| BronchitisInfections and infestations | 3/601 | 24/585 | 27/601 | 6/306 | 3/137 | 34/601 |
| Back painMusculoskeletal and connective tissue disorders | 4/601 | 19/585 | 21/601 | 5/306 | 6/137 | 32/601 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/601 | 23/585 | 24/601 | 5/306 | 5/137 | 31/601 |
| Age, Continuous(years) | Core Treatment |
|---|---|
| Mean | 55.0 ± 11.20 |
| Sex: Female, Male(Participants) | Core Treatment |
|---|---|
| Female | 271 |
| Male | 330 |
The record gives a start of Oct 2006, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aliskiren · Valsartan